Literature DB >> 18077783

Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vasculitis: the cause is hidden, but the result is known.

Robert A F de Lind van Wijngaarden1, Leendert van Rijn, E Christiaan Hagen, Richard A Watts, Gina Gregorini, Jan Willem Cohen Tervaert, Alfred D Mahr, John L Niles, Emile de Heer, Jan A Bruijn, Ingeborg M Bajema.   

Abstract

The first description of what is now known as antineutrophil cytoplasmic autoantibody-associated necrotizing vasculitis appeared more than 140 yr ago. Since then, many aspects of the pathogenic pathway have been elucidated, indicating the involvement of antineutrophil cytoplasmic autoantibodies, but why antineutrophil cytoplasmic autoantibodies are produced in the first place remains unknown. Over the years, many hypotheses have emerged addressing the etiology of antineutrophil cytoplasmic antibody production, but no exclusive factor or set of factors can so far be held responsible. Herein is reviewed the most influential hypotheses regarding the causes of antineutrophil cytoplasmic antibody-associated vasculitis with the aim of placing in an epidemiologic background the different hypotheses that are centered on environmental and genetic influences.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18077783     DOI: 10.2215/CJN.03550807

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  27 in total

Review 1.  ANCA-associated vasculitides--advances in pathogenesis and treatment.

Authors:  Min Chen; Cees G M Kallenberg
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Characteristics and prognosis of microscopic polyangiitis with bronchiectasis.

Authors:  Hiroki Tashiro; Koichiro Takahashi; Masahide Tanaka; Kazutoshi Komiya; Tomomi Nakamura; Shinya Kimura; Yoshifumi Tada; Naoko Sueoka-Aragane
Journal:  J Thorac Dis       Date:  2017-02       Impact factor: 2.895

Review 3.  [Skin diseases due to systemic vasculitides and vasculopathies].

Authors:  S Volc; J C Maier; M Röcken
Journal:  Hautarzt       Date:  2016-12       Impact factor: 0.751

4.  Epitope specificity of myeloperoxidase antibodies: identification of candidate human immunodominant epitopes.

Authors:  B F Bruner; E S Vista; D M Wynn; J A James
Journal:  Clin Exp Immunol       Date:  2011-03-14       Impact factor: 4.330

5.  ANCA as a predictor of relapse: useful in patients with renal involvement but not in patients with nonrenal disease.

Authors:  Michael J Kemna; Jan Damoiseaux; Jos Austen; Bjorn Winkens; Jim Peters; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2014-10-16       Impact factor: 10.121

Review 6.  The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis.

Authors:  Lisa C Willcocks; Paul A Lyons; Andrew J Rees; Kenneth G C Smith
Journal:  Arthritis Res Ther       Date:  2010-02-15       Impact factor: 5.156

Review 7.  Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity.

Authors:  James M Kelley; Jeffrey C Edberg; Robert P Kimberly
Journal:  Clin Immunol       Date:  2009-05-23       Impact factor: 3.969

8.  Microscopic polyangiitis triggered by recurrent methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Rahil Kasmani; Kelechi Okoli; Kalpana Naraharisetty; William Gunning; Joseph I Shapiro; Shobha Ratnam
Journal:  Int Urol Nephrol       Date:  2009-10-01       Impact factor: 2.370

Review 9.  Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.

Authors:  Marc Hilhorst; Pieter van Paassen; Jan Willem Cohen Tervaert
Journal:  J Am Soc Nephrol       Date:  2015-05-08       Impact factor: 10.121

10.  CD45RC isoform expression identifies functionally distinct T cell subsets differentially distributed between healthy individuals and AAV patients.

Authors:  Laurence Ordonez; Isabelle Bernard; Fatima-Ezzahra L'faqihi-Olive; Jan Willem Cohen Tervaert; Jan Damoiseaux; Abdelhadi Saoudi
Journal:  PLoS One       Date:  2009-04-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.